Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIST-RIC: Histological Response After Neoadjuvant Chemo-Radio and Immediate Reconstruction
NCT02679040Phase 2Unknown
- Sponsor
- Institut Paoli-Calmettes
- Start
- Jan 2016
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, trastuzumab in breast cancer, sponsored by Institut Paoli-Calmettes. Status: unknown.
02
Drugs
docetaxeltrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02679040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679040.